학술논문
1362MO Pembrolizumab + olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study
Document Type
Abstract
Author
Source
In Annals of Oncology September 2022 33 Supplement 7:S1163-S1164
Subject
Language
ISSN
0923-7534